SMARTSTREAM-TECHNOLOGIES
12.10.2021 09:02:08 CEST | Business Wire | Press release
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM® ) solutions provider, today announces that Fisher & Paykel Appliances, the global manufacturer of household appliances, operating in over 50 countries, has signed with SmartStream Air - providing the firm’s finance team with cloud-native, AI technology for bank reconciliations.
As a leading appliance manufacturer headquartered in New Zealand, Fisher & Paykel Appliances approached SmartStream to evaluate their data management and reconciliations tooling. SmartStream Air is agnostic to structured data formats requiring zero IT skillset to use, and will automate the finance division’s data reconciliation processing, at speed. The AI solution will easily integrate with Fisher & Paykel Appliances’ existing systems enabling them to perform additional analytics on reconciled data. In addition, it will provide business intelligence by connecting to third-party tools already deployed in-house.
SmartStream Air’s software as a service (SaaS) ease of deployment in numerous locations was a key deciding factor as Fisher & Paykel Appliances will look to roll out the product in New Zealand, followed by multiple locations in Asia Pacific and then globally. The company was looking to automate and enhance their currently manual reconciliation operating model to support their growing business volumes globally.
The process to proof-of-concept for SmartStream Air was quick in comparison to the three other competitor reconciliation solutions that were under consideration. As a self-service, AI enabled, cloud-native application, agnostic to structured data formats and data reconciliation types, with little configuration to setup, the go-live was immediate with higher levels of productivity to meet the growing business at Fisher & Paykel.
Nicole Adamson, Senior Corporate Controller, Fisher & Paykel, states: “We are pleased to partner with SmartStream, it is in our interest to keep up with the latest technologies and always improve our internal processes and productivity. We needed to move away from the manual operations to an automated data reconciliation model, which eliminates operational risk, whilst being able to scale volumes more cost-effectively. We felt SmartStream Air was the right choice to help us achieve this objective”.
Victoria Harverson, Global Head of Business Development for SmartStream Air, comments: “We are delighted to have Fisher and Paykel as a SmartStream Air customer. This partnership is significant as it recognises our deepening footprint in New Zealand, whilst also establishing a new relationship with a customer in the manufacturing sector. SmartStream Air is perfect for this type of operating model and really showcases how easy and cost-effective it can be for a company finance team to quickly control risk and see real tangible ROI by leveraging the latest self-service AI tooling”.
With SmartStream Air users can use the power of AI to autonomously build and learn data matching behaviour, transforming typical data reconciliation tasks – reducing the time it takes to just seconds. Speed of go-to-market and scalability was also a winning factor as SmartStream Air has been designed to be live the same day and is built for performance when it comes to high-volume processing.
Ends
About Fisher & Paykel
Fisher & Paykel Appliances has been designing products since 1934 and has grown into a global company with products sold in more than 50 countries around the world.
Our design heritage is founded on a pioneering spirit and a culture of curiosity. We’ve built our legacy with a future focus that still stays true to the fundamentals of sustainable design. We believe technology should always begin with the people who use it. This has seen us challenge conventional appliance design to create products that deliver to genuine human need.
Our ongoing research and development is backed by a culture of open innovation, collaboration and curiosity – one that seeks to uncover insights and ideas that connect with our customers and respect our planet.
About SmartStream
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005110/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom